Stock analysts at StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a note issued to investors on Thursday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Price Performance
TTNP opened at $5.31 on Thursday. The stock’s 50-day moving average price is $6.50 and its 200 day moving average price is $6.81. Titan Pharmaceuticals has a 12-month low of $5.00 and a 12-month high of $13.97.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last issued its quarterly earnings results on Wednesday, May 15th. The specialty pharmaceutical company reported ($1.24) earnings per share (EPS) for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Read More
- Five stocks we like better than Titan Pharmaceuticals
- Are Penny Stocks a Good Fit for Your Portfolio?
- Constellation Brands Stock Q1 2025: Crushing Anheuser-Busch?
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Qualcomm Stock Continues to Rise in the Face of Negative News
- The How And Why of Investing in Oil Stocks
- Top 3 Summer Stocks with Solid Growth Opportunities
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
